ArticleJournal of community hospital internal medicine perspectives2026
Severe Spontaneous Hematoma in an Elderly Female: A Case of Acquired Hemophilia A.
Article in Journal of community hospital internal medicine perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acquired Hemophilia A (AHA) is a rare but serious autoimmune disorder characterized by the development of autoantibodies against coagulation factor VIII (FVIII), leading to spontaneous bleeding in individuals without a personal or family history of bleeding disorders. The incidence of AHA is approximately 1.5 cases per million per year, with a higher prevalence in the elderly. This case report describes an 87-year-old female who presented with extensive bruising and was found to have profoundly low FVIII levels, and elevated FVIII inhibitor levels confirming a diagnosis of AHA. Management included recombinant activated factor VII (rFVIIa), porcine FVIII (Obizur), corticosteroids, and rituximab, leading to clinical stabilization. We also review diagnostic criteria, the role of inhibitor levels in monitoring, and current treatment guidelines, including the emerging role of emicizumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.